Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JMKX001899 + IN10018
- Development stage
- Unknown
- Lead developer
- InxMed (Shanghai) Co., Ltd.
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JMKX001899 + IN10018 is a combination therapy under clinical investigation for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation. JMKX001899 (also known as Sosimerasib) is an orally available, covalent inhibitor of the oncogenic KRAS G12C mutation, acting as a targeted therapy with antineoplastic effects. IN10018 (also known as Ifebemtinib or BI-853520) is an orally bioavailable, highly potent and selective small molecule inhibitor of focal adhesion kinase (FAK), which targets pathways involved in tumor proliferation, survival, migration, invasion, and microenvironment modulation. The combination represents a strategy to overcome resistance to KRAS G12C inhibition by targeting complementary oncogenic pathways, aiming to increase clinical efficacy in difficult-to-treat NSCLC. Current development is in Phase 1 clinical trials for KRAS G12C-mutated NSCLC.
- Other names
- Sosimerasib + Ifebemtinib
02
Targets
FAK (Focal adhesion kinase)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)
Beyond the preview
Go deeper on JMKX001899 + IN10018.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JMKX001899 + IN10018.